Full-Time

Principal Enterprise Architect

GMP Systems

Confirmed live in the last 24 hours

Cellares

Cellares

201-500 employees

Develops and manufactures cell therapies efficiently

Compensation Overview

$140k - $240k/yr

Expert

Bridgewater Township, NJ, USA

The job is onsite in Bridgewater, NJ, and does not mention any remote work options.

Category
IT Project Management
IT & Security
Requirements
  • Bachelor’s degree in computer science or related technical field
  • A minimum of 10+ years within IT in a cGMP environment in the biotech/biopharma industry with a minimum of 5 years leadership experience. Cell/Gene Therapy and CDMO experience a plus
  • Experience Implementing Manufacturing, Quality, and Supply Chain applications, including ERP, MES, LIMS, QMS, etc.
  • Must be able to manage shifting priorities to meet critical deadlines in a fast-paced and dynamic, growing environment while providing clear direction to team member
  • History of developing and building cohesive, high-performing teams with a strong sense of mission, providing training and mentoring to build sufficient management depth throughout the organization and ensure strong succession planning
  • Strong analytical, problem-solving and critical thinking skills and the ability to lead as a change agent to promote flexibility, creativity, and accountability
  • Excellent teamwork and interpersonal skills with ability to influence and build strong working relationships at all levels within the organization
  • Excellent organizational and communication skills
  • Self-motivated and passionate about advancing the field of cell therapy
  • Self-awareness, integrity, authenticity, and a growth mindset
Responsibilities
  • Oversee the global IT function for GMP systems, ensuring consistency, scalability, and compliance across all regions
  • Develop and maintain a comprehensive technical blueprint for GMP systems, aligning technology services with business objectives and regulatory requirements
  • Provide architectural leadership in resolving inter-program and inter-project issues related to GMP systems
  • Oversee the hiring, development, and performance management of staff within IT GMP Systems
  • Partner with the IDMO Business to develop and execute against an IT roadmap and deliver on the IT infrastructure needed to manufacture autologous and allogeneic cell therapy products
  • Drive the selection, implementation, and support of various business applications, including ERP, MES, LIMS, QMS, etc.
  • Work closely with Validation and Quality in deploying and supporting IT GMP Systems
  • Manage and coordinate employees, contractors, and agencies, contractors involved in development projects to ensure alignment with project goals, timelines, budgets, and quality standards
  • Establish KPIs, monitor progress, and keep critical stakeholders informed of progress for IT projects and strategic initiatives
  • Establish key stakeholder relationships with internal and external stakeholders
  • Work closely with other functional areas to develop and execute against the strategic plan for all Cellares sites
  • Develop, manage, and track a budget for the department
  • Negotiates and contracts with consultants, technical personnel, and vendors for services and products needed to support the IDMO IT infrastructure
  • Serve as a subject matter expert (SME) during audits or inspections by regulatory authorities.

Cellares develops and manufactures cell therapies in the biotechnology sector, operating as an Integrated Development and Manufacturing Organization (IDMO) that combines these processes in one facility. Its proprietary "Smart Factory" technology features an automated single-use cartridge system, which increases productivity by ten times and reduces costs and process failures significantly compared to traditional methods. The company serves a range of clients, including pharmaceutical companies, and stands out due to its competitive pricing and efficiency. Cellares aims to make the manufacturing of cell therapies more accessible and cost-effective.

Company Size

201-500

Company Stage

Series C

Total Funding

$355M

Headquarters

South San Francisco, California

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with Bristol Myers Squibb secures $380M for CAR T cell therapy manufacturing.
  • Ossama Eissa's appointment as COO strengthens global Smart Factory expansion efforts.
  • Sony partnership enhances precision in cell therapy manufacturing with advanced flow cytometry.

What critics are saying

  • Emerging competition from companies like bluebird bio threatens Cellares' market share.
  • Rapid Smart Factory expansion may face logistical challenges in international markets.
  • Over-reliance on Bristol Myers Squibb partnership could be risky if dynamics change.

What makes Cellares unique

  • Cellares' Cell Shuttle offers 10x scalability over manual cell therapy manufacturing processes.
  • The Smart Factory technology integrates development and manufacturing, unlike traditional CDMOs.
  • Cell Q automates QC for up to 6,000 batches, reducing manual labor and costs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

3%

2 year growth

5%
RegMedNet
Apr 3rd, 2025
Cell therapy weekly: regulatory boost for automated cell therapy production platform

bluebird bio announced on 21 February 2025 that it had entered into a definitive agreement to be acquired global investment firms Carlyle (DC, USA) and SK Capital (NY, USA) for US$3.00 per share in cash, plus a contingent value right of $6.84 per share if certain sales targets are met.

ROI-NJ
Nov 13th, 2024
Cellares appoints former Novartis, Lonza and Legend Biopharma exec as COO

Cellares, a Bridgewater-based leader in automated cell therapy manufacturing, on Monday announced it appointed Ossama Eissa, former executive at Novartis, Lonza Biologics, and Legend Biotech, as chief operating officer.

ROI-NJ
Nov 13th, 2024
Cellares Appoints Former Novartis, Lonza And Legend Biopharma Exec As Coo

Cellares, a Bridgewater-based leader in automated cell therapy manufacturing, on Monday announced it appointed Ossama Eissa, former executive at Novartis, Lonza Biologics, and Legend Biotech, as chief operating officer.Eissa’s extensive experience will support the expansion of Cellares’ Smart Factory network in the United States, Europe, Japan and other international markets, addressing the challenges of scalability, cost, and quality that have long hindered patient access. Through these advancements, Cellares will work to ensure that life-saving treatments are accessible for oncology and autoimmune patients globally.This appointment strengthens the Cellares leadership team in a time of rapid global expansion of the company’s IDMO manufacturing services, in response to the growing global demand for cell therapy manufacturing capacity.Eissa brings more than 20 years of experience in pharmaceutical and biotech manufacturing.He formerly served as vice president and general manager at Legend Biotech, where he led the Raritan production site through the global launch of Carvykti, a CAR-T cell therapy.At Lonza Biologics, Eissa managed Global Strategic Projects, contributing significantly to the Cell and Gene Technologies Business Unit by boosting manufacturing efficiency and driving commercial scale-up. He also oversaw U.S. manufacturing operations at Novartis, scaling production and supporting regulatory approval for Kymriah, the first FDA-approved CAR-T cell therapy.“Joining Cellares is an opportunity to address one of the biggest challenges in healthcare today: making cell therapies accessible to all of those who need them,” Eissa said. “The mission aligns closely with my experience in scaling complex manufacturing systems to benefit patients directly. I’ve witnessed the profound impact these treatments have, and I’m committed to ensuring that we reach more patients, especially those facing cancer and autoimmune diseases, with the reliability and speed they deserve.”

BioProcess International
Sep 12th, 2024
Cellares and Sony partner to automate cell therapy manufacturing

Self-acclaimed integrated development and manufacturing organization (IDMO) Cellares has partnered with Sony Corporation, a technology firm focused on the field of flow cytometry, to integrate advanced flow cytometry-based cell analysis and sorting solutions into the Cellares Cell Shuttle platform.

Contract Pharma
Sep 3rd, 2024
Cellares Appoints CFO and General Counsel

Cellares, a leader in cell therapy manufacturing and an Integrated Development and Manufacturing Organization (IDMO), has appointed Justin McAnear as Chief Financial Officer (CFO) and Jonathan Butler as General Counsel and Corporate Secretary (GC).